H.C. Wainwright lowered the firm’s price target on Astria Therapeutics to $18 from $20 and keeps a Buy rating on the shares after the company entered into an exclusive worldwide agreement with Ichnos Sciences to develop an OX40 portfolio for the potential treatment of atopic dermatitis, with the possibility for expansion into additional allergic and immunological indications.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ATXS:
- Astria Therapeutics prices $64M underwritten offering
- Astria Therapeutics to pay $15M upfront license fee
- Astria Therapeutics enters exclusive OX40 license agreement with Ichnos Sciences
- Astria publishes data supporting STAR-0215′ profile as HAE treatment
- 2 ‘Strong Buy’ Stocks Under $10 That Oppenheimer Sees Surging Over 200% — Here’s Why They Could Jump
